Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 340

1.

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.

Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM, Foung SK.

J Virol. 2009 Jun;83(12):6149-60. doi: 10.1128/JVI.00248-09. Epub 2009 Mar 25.

2.

Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK.

PLoS Pathog. 2012;8(4):e1002653. doi: 10.1371/journal.ppat.1002653. Epub 2012 Apr 12.

3.

Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA, Foung SK.

J Virol. 2011 Oct;85(20):10451-63. doi: 10.1128/JVI.05259-11. Epub 2011 Aug 3.

4.

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK.

Hepatology. 2006 Mar;43(3):592-601.

PMID:
16496330
5.

Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.

Gu J, Hardy J, Boo I, Vietheer P, McCaffrey K, Alhammad Y, Chopra A, Gaudieri S, Poumbourios P, Coulibaly F, Drummer HE.

J Virol. 2018 Apr 13;92(9). pii: e02066-17. doi: 10.1128/JVI.02066-17. Print 2018 May 1.

6.

Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.

Keck ZY, Op De Beeck A, Hadlock KG, Xia J, Li TK, Dubuisson J, Foung SK.

J Virol. 2004 Sep;78(17):9224-32.

7.

Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK.

J Virol. 2000 Nov;74(22):10407-16.

8.

Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, Foung SK, Ball JK, Patel AH.

J Gen Virol. 2008 Mar;89(Pt 3):653-9. doi: 10.1099/vir.0.83386-0.

9.

Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.

Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK.

J Virol. 2008 Jun;82(12):6061-6. doi: 10.1128/JVI.02475-07. Epub 2008 Apr 9.

10.

Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.

Anjum S, Wahid A, Afzal MS, Albecka A, Alsaleh K, Ahmad T, Baumert TF, Wychowski C, Qadri I, Penin F, Dubuisson J.

J Infect Dis. 2013 Dec 1;208(11):1888-97. doi: 10.1093/infdis/jit376. Epub 2013 Aug 1.

PMID:
23908491
11.

Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423.

Keck ZY, Angus AG, Wang W, Lau P, Wang Y, Gatherer D, Patel AH, Foung SK.

PLoS Pathog. 2014 Aug 14;10(8):e1004297. doi: 10.1371/journal.ppat.1004297. eCollection 2014 Aug.

12.

Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

Tarr AW, Owsianka AM, Jayaraj D, Brown RJ, Hickling TP, Irving WL, Patel AH, Ball JK.

J Gen Virol. 2007 Nov;88(Pt 11):2991-3001.

PMID:
17947521
13.

Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.

Keck ZY, Xia J, Cai Z, Li TK, Owsianka AM, Patel AH, Luo G, Foung SK.

J Virol. 2007 Jan;81(2):1043-7. Epub 2006 Nov 1.

14.

In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.

Gal-Tanamy M, Keck ZY, Yi M, McKeating JA, Patel AH, Foung SK, Lemon SM.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19450-5. doi: 10.1073/pnas.0809879105. Epub 2008 Dec 3.

15.

Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection.

Alhammad YM, Maharajh S, Butcher R, Eden JS, White PA, Poumbourios P, Drummer HE.

PLoS One. 2015 May 13;10(5):e0126397. doi: 10.1371/journal.pone.0126397. eCollection 2015.

16.

Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422.

Sandomenico A, Leonardi A, Berisio R, Sanguigno L, Focà G, Focà A, Ruggiero A, Doti N, Muscariello L, Barone D, Farina C, Owsianka A, Vitagliano L, Patel AH, Ruvo M.

J Virol. 2016 Jan 27;90(7):3745-59. doi: 10.1128/JVI.02397-15.

17.

Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.

Keck ZY, Girard-Blanc C, Wang W, Lau P, Zuiani A, Rey FA, Krey T, Diamond MS, Foung SK.

J Virol. 2016 Jan 6;90(6):3112-22. doi: 10.1128/JVI.02458-15.

18.

Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2.

Keck ZY, Li TK, Xia J, Bartosch B, Cosset FL, Dubuisson J, Foung SK.

J Virol. 2005 Nov;79(21):13199-208.

19.

Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.

Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J, Persson MA.

Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16269-74. Epub 2007 Oct 2.

20.

Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.

Rafique S, Idrees M, Ali A, Iqbal M.

Mol Biol Rep. 2014 Jun;41(6):3945-50. doi: 10.1007/s11033-014-3262-y. Epub 2014 Feb 25.

PMID:
24566682

Supplemental Content

Support Center